• Atrium Therapeutics identified nearly 2,000 individuals with PRKAG2 mutations through a subset of engaged genetic-testing labs.
• The findings suggest PRKAG2 syndrome prevalence exceeds the initial estimate of 1,000-2,000 patients.
• ATR1072 improved cardiac relaxation and atrial signaling in preclinical studies at 24 weeks following three doses of 3 mg/kg.
• A nine-month repeat-dose monkey study found no dose-limiting toxicity at the highest dose tested or effects on cardiac function.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.